Japanese Generic Drug Maker Towa Invests ¥20 Billion To Increase Capacity
This article was originally published in PharmAsia News
Executive Summary
Major Japanese generic drug maker Towa Pharmaceutical will invest ¥20 billion to build a new factory in Yamagata Prefecture. To be completed in 2012, the new facility will have an annual production capacity of 7.5 billion tablets and 50 million injections, which is 1.5 times larger than its current site. Towa expects further expansion in the Japanese generic drug market due to the national policy of restraining medical costs.(Click here for more - Japanese languageYou may also be interested in...
QUOTED. 13 December 2019. Todd Garner
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Real-World Evidence Fails Another Test At US FDA
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports